Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Management of Pregnancy in Women With Chronic Myeloid Leukemia.

Ross DM, Burbury KL, Grigg AP, Hughes TP, Seymour JF.

J Clin Oncol. 2018 May 31:JCO2018786137. doi: 10.1200/JCO.2018.78.6137. [Epub ahead of print] No abstract available.

PMID:
29851544
2.

Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten.

Nair SS, Luu PL, Qu W, Maddugoda M, Huschtscha L, Reddel R, Chenevix-Trench G, Toso M, Kench JG, Horvath LG, Hayes VM, Stricker PD, Hughes TP, White DL, Rasko JEJ, Wong JJ, Clark SJ.

Epigenetics Chromatin. 2018 May 28;11(1):24. doi: 10.1186/s13072-018-0194-0.

3.

Global warming transforms coral reef assemblages.

Hughes TP, Kerry JT, Baird AH, Connolly SR, Dietzel A, Eakin CM, Heron SF, Hoey AS, Hoogenboom MO, Liu G, McWilliam MJ, Pears RJ, Pratchett MS, Skirving WJ, Stella JS, Torda G.

Nature. 2018 Apr;556(7702):492-496. doi: 10.1038/s41586-018-0041-2. Epub 2018 Apr 18.

PMID:
29670282
4.

Increasing thermal stress for tropical coral reefs: 1871-2017.

Lough JM, Anderson KD, Hughes TP.

Sci Rep. 2018 Apr 17;8(1):6079. doi: 10.1038/s41598-018-24530-9.

5.

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.

Eadie LN, Hughes TP, White DL.

Leukemia. 2018 Mar 23. doi: 10.1038/s41375-018-0101-5. [Epub ahead of print] No abstract available.

PMID:
29654270
6.

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.

Eadie LN, Saunders VA, Branford S, White DL, Hughes TP.

Oncotarget. 2018 Feb 3;9(17):13423-13437. doi: 10.18632/oncotarget.24393. eCollection 2018 Mar 2.

7.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086. [Epub ahead of print]

PMID:
29567798
8.

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.

McClure BJ, Heatley SL, Kok CH, Sadras T, An J, Hughes TP, Lock RB, Yeung D, Sutton R, White DL.

Br J Cancer. 2018 Apr;118(7):1000-1004. doi: 10.1038/s41416-018-0022-0. Epub 2018 Mar 13.

PMID:
29531323
9.

Biogeographical disparity in the functional diversity and redundancy of corals.

McWilliam M, Hoogenboom MO, Baird AH, Kuo CY, Madin JS, Hughes TP.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3084-3089. doi: 10.1073/pnas.1716643115. Epub 2018 Mar 5.

PMID:
29507193
10.

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP.

Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20.

PMID:
29459949
11.

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells.

Eadie LN, Dang P, Goyne JM, Hughes TP, White DL.

PLoS One. 2018 Jan 31;13(1):e0192180. doi: 10.1371/journal.pone.0192180. eCollection 2018.

12.

A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.

Broughton SE, Hercus TR, Nero TL, Kan WL, Barry EF, Dottore M, Cheung Tung Shing KS, Morton CJ, Dhagat U, Hardy MP, Wilson NJ, Downton MT, Schieber C, Hughes TP, Lopez AF, Parker MW.

Nat Commun. 2018 Jan 26;9(1):386. doi: 10.1038/s41467-017-02633-7.

13.

Spatial and temporal patterns of mass bleaching of corals in the Anthropocene.

Hughes TP, Anderson KD, Connolly SR, Heron SF, Kerry JT, Lough JM, Baird AH, Baum JK, Berumen ML, Bridge TC, Claar DC, Eakin CM, Gilmour JP, Graham NAJ, Harrison H, Hobbs JA, Hoey AS, Hoogenboom M, Lowe RJ, McCulloch MT, Pandolfi JM, Pratchett M, Schoepf V, Torda G, Wilson SK.

Science. 2018 Jan 5;359(6371):80-83. doi: 10.1126/science.aan8048.

PMID:
29302011
14.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure.

Marum JE, Yeung DT, Purins L, Reynolds J, Parker WT, Stangl D, Wang PPS, Price DJ, Tuke J, Schreiber AW, Scott HS, Hughes TP, Branford S.

Blood Adv. 2017 Jul 31;1(18):1369-1381. doi: 10.1182/bloodadvances.2017006825. eCollection 2017 Aug 8.

15.

Large-scale bleaching of corals on the Great Barrier Reef.

Hughes TP, Kerry JT, Simpson T.

Ecology. 2018 Feb;99(2):501. doi: 10.1002/ecy.2092. Epub 2017 Dec 18.

PMID:
29155453
16.

First Approved Kinase Inhibitor for AML.

Rasko JEJ, Hughes TP.

Cell. 2017 Nov 16;171(5):981. doi: 10.1016/j.cell.2017.11.007.

PMID:
29149610
17.

A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.

Sadras T, Heatley SL, Kok CH, McClure BJ, Yeung D, Hughes TP, Sutton R, Ziegler DS, White DL.

Cancer Genet. 2017 Oct;216-217:86-90. doi: 10.1016/j.cancergen.2017.07.008. Epub 2017 Jul 31.

PMID:
29025600
18.

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.

Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, McClure B, Venn N, Moore S, Suttle J, Law T, Ng A, Muskovic W, Norris MD, Revesz T, Osborn M, Moore AS, Suppiah R, Fraser C, Alvaro F, Hughes TP, Mullighan CG, Marshall GM, Pozza LD, Yeung DT, Sutton R, White DL.

Haematologica. 2017 Dec;102(12):e490-e493. doi: 10.3324/haematol.2016.162925. Epub 2017 Sep 21. No abstract available.

19.

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.

Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, Revesz T, Moore AS, Hughes TP, Yeung D, Sutton R, White DL.

Cancer Lett. 2017 Nov 1;408:92-101. doi: 10.1016/j.canlet.2017.08.034. Epub 2017 Sep 1.

PMID:
28866095
20.

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH.

Leukemia. 2017 Nov;31(11):2529-2531. doi: 10.1038/leu.2017.247. Epub 2017 Aug 3. No abstract available.

21.

A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia.

Pagani IS, Kok CH, Saunders VA, Van der Hoek MB, Heatley SL, Schwarer AP, Hahn CN, Hughes TP, White DL, Ross DM.

J Mol Diagn. 2017 Sep;19(5):711-721. doi: 10.1016/j.jmoldx.2017.05.009. Epub 2017 Jul 18.

PMID:
28732215
22.

Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.

Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, Quach H, Pavlovsky C, Louw VJ, Shih LY, Turkina AG, Meillon L, Jin Y, Acharya S, Dalal D, Lipton JH.

Br J Haematol. 2017 Oct;179(2):219-228. doi: 10.1111/bjh.14829. Epub 2017 Jul 12.

23.

Coral reefs in the Anthropocene.

Hughes TP, Barnes ML, Bellwood DR, Cinner JE, Cumming GS, Jackson JBC, Kleypas J, van de Leemput IA, Lough JM, Morrison TH, Palumbi SR, van Nes EH, Scheffer M.

Nature. 2017 May 31;546(7656):82-90. doi: 10.1038/nature22901. Review.

PMID:
28569801
24.

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.

Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR.

Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22.

PMID:
28329763
25.

Global warming and recurrent mass bleaching of corals.

Hughes TP, Kerry JT, Álvarez-Noriega M, Álvarez-Romero JG, Anderson KD, Baird AH, Babcock RC, Beger M, Bellwood DR, Berkelmans R, Bridge TC, Butler IR, Byrne M, Cantin NE, Comeau S, Connolly SR, Cumming GS, Dalton SJ, Diaz-Pulido G, Eakin CM, Figueira WF, Gilmour JP, Harrison HB, Heron SF, Hoey AS, Hobbs JA, Hoogenboom MO, Kennedy EV, Kuo CY, Lough JM, Lowe RJ, Liu G, McCulloch MT, Malcolm HA, McWilliam MJ, Pandolfi JM, Pears RJ, Pratchett MS, Schoepf V, Simpson T, Skirving WJ, Sommer B, Torda G, Wachenfeld DR, Willis BL, Wilson SK.

Nature. 2017 Mar 15;543(7645):373-377. doi: 10.1038/nature21707.

PMID:
28300113
26.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

27.

A unified model explains commonness and rarity on coral reefs.

Connolly SR, Hughes TP, Bellwood DR.

Ecol Lett. 2017 Apr;20(4):477-486. doi: 10.1111/ele.12751. Epub 2017 Mar 2.

PMID:
28251798
28.

Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML.

Hughes TP, Ross DM.

Nat Rev Clin Oncol. 2017 Apr;14(4):201-202. doi: 10.1038/nrclinonc.2017.11. Epub 2017 Feb 7. No abstract available.

PMID:
28169304
29.

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.

Wang J, Lu L, Kok CH, Saunders VA, Goyne JM, Dang P, Leclercq TM, Hughes TP, White DL.

Haematologica. 2017 May;102(5):843-853. doi: 10.3324/haematol.2016.153270. Epub 2017 Feb 2.

30.

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

Hughes A, Clarson J, Gargett T, Yu W, Brown MP, Lopez AF, Hughes TP, Yong AS.

Leuk Res. 2017 Apr;55:55-57. doi: 10.1016/j.leukres.2017.01.009. Epub 2017 Jan 9. No abstract available.

PMID:
28129558
31.

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, Yong AS.

Blood. 2017 Mar 2;129(9):1166-1176. doi: 10.1182/blood-2016-10-745992. Epub 2017 Jan 3.

32.

CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.

Barratt DT, Cox HK, Menelaou A, Yeung DT, White DL, Hughes TP, Somogyi AA.

Clin Pharmacokinet. 2017 Aug;56(8):977-985. doi: 10.1007/s40262-016-0494-0.

PMID:
27995529
33.

Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'

Eadie LN, Hughes TP, White DL.

Leukemia. 2017 Mar;31(3):769-770. doi: 10.1038/leu.2016.335. Epub 2016 Dec 2. No abstract available.

PMID:
27909344
34.

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines.

Eadie LN, Hughes TP, White DL.

PLoS One. 2016 Aug 18;11(8):e0161470. doi: 10.1371/journal.pone.0161470. eCollection 2016.

35.

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL.

Leukemia. 2017 Jan;31(1):75-82. doi: 10.1038/leu.2016.179. Epub 2016 Jun 24.

PMID:
27416909
36.

A critique of claims for negative impacts of Marine Protected Areas on fisheries.

Hughes TP, Cameron DS, Chin A, Connolly SR, Day JC, Jones GP, McCook L, McGinnity P, Mumby PJ, Pears RJ, Pressey RL, Russ GR, Tanzer J, Tobin A, Young MA.

Ecol Appl. 2016 Mar;26(2):637-41. No abstract available.

PMID:
27209801
37.

Chronic myeloid leukemia: reminiscences and dreams.

Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ.

Haematologica. 2016 May;101(5):541-58. doi: 10.3324/haematol.2015.139337. Review.

38.

Moving treatment-free remission into mainstream clinical practice in CML.

Hughes TP, Ross DM.

Blood. 2016 Jul 7;128(1):17-23. doi: 10.1182/blood-2016-01-694265. Epub 2016 Mar 24.

39.

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, Grose R, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL.

Leukemia. 2016 Jun;30(6):1263-72. doi: 10.1038/leu.2016.34. Epub 2016 Feb 22.

PMID:
26898188
40.

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM.

Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3.

41.

BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.

Latham S, Bartley PA, Budgen B, Ross DM, Hughes E, Branford S, White D, Hughes TP, Morley AA.

J Clin Pathol. 2016 Sep;69(9):817-21. doi: 10.1136/jclinpath-2015-203538. Epub 2016 Feb 2.

PMID:
26837312
42.

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S.

Blood. 2016 Apr 14;127(15):1870-80. doi: 10.1182/blood-2015-09-666214. Epub 2016 Jan 14.

43.

Global marine protected areas do not secure the evolutionary history of tropical corals and fishes.

Mouillot D, Parravicini V, Bellwood DR, Leprieur F, Huang D, Cowman PF, Albouy C, Hughes TP, Thuiller W, Guilhaumon F.

Nat Commun. 2016 Jan 12;7:10359. doi: 10.1038/ncomms10359.

44.

China's Degraded Environment Enters A New Normal.

Zhang K, Dearing JA, Tong SL, Hughes TP.

Trends Ecol Evol. 2016 Mar;31(3):175-177. doi: 10.1016/j.tree.2015.12.002. Epub 2016 Jan 2.

PMID:
26753784
45.

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials.

le Coutre PD, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Gooden K, Wallis N, Cortes JE.

Leukemia. 2016 Jul;30(7):1593-6. doi: 10.1038/leu.2015.352. Epub 2015 Dec 21. No abstract available.

46.

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S.

Blood. 2016 Feb 11;127(6):703-12. doi: 10.1182/blood-2015-08-660977. Epub 2015 Nov 24.

47.

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

Yeung DT, Tang C, Vidovic L, White DL, Branford S, Hughes TP, Yong AS.

Blood. 2015 Dec 17;126(25):2720-3. doi: 10.1182/blood-2015-07-655589. Epub 2015 Oct 23.

48.

Living with CML: is death no longer the end (point)?

White DL, Hughes TP.

Blood. 2015 Jul 2;126(1):2-4. doi: 10.1182/blood-2015-05-644732. No abstract available.

49.

Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia.

Ong J, Yeung D, Filshie R, Hughes TP, Nandurkar H.

Int J Hematol. 2015 Nov;102(5):639-42. doi: 10.1007/s12185-015-1824-y. Epub 2015 Jul 2.

PMID:
26134364
50.

OCT1 and imatinib transport in CML: is it clinically relevant?

Watkins DB, Hughes TP, White DL.

Leukemia. 2015 Oct;29(10):1960-9. doi: 10.1038/leu.2015.170. Epub 2015 Jul 9. Review.

PMID:
26122430

Supplemental Content

Loading ...
Support Center